Navigation Links
Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/27/2007

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced it is continuing to enroll new patients in the maximum tolerated dose cohort expansion segment of its Phase 1/2a trial for patients with cancers of the gastrointestinal tract that express the RAAG12 antigen.

RAAG12 is a glycotope (sugar structure) that is widely found on the surface of tumor cells of many kinds of cancer, particularly cancers of the gastrointestinal tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead clinical monoclonal antibody drug candidate, targets the RAAG12 antigen.

This segment of the trial will yield additional information about the safety of the drug and define the pharmacokinetics of the antibody.

The appropriate dose and schedule of RAV12 was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 patients. This trial revealed that a fractionated dosing regimen provided an improved safety profile for the antibody. Raven is now enrolling patients in a second segment of the trial in which all patients are receiving the recommended dose and schedule of drug. Information from the Phase 1/2a trial will be supporting the dosing in a Phase 2 study in pancreatic cancer, the next clinical trial scheduled for RAV12.

The trial is being conducted at five institutions in the United States: The Sarah Cannon Cancer Center in Nashville, TN; The Fox Chase Cancer Center in Philadelphia, PA; Premiere Oncology in Santa Monica, CA; Georgetown University Medical Center in Washington, DC; and The University of Miami Medical Center in Miami, FL.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly tho
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... , March 27, 2015 Across the global ... meeting challenges in clinical development, market education, and regulatory ... the Medical Affairs function is expected to increase in ... According to research by benchmarking firm, ... a group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... today announced the issuance of an aggregate of 30,000 ... and an aggregate of 120,500 stock options to employees ... vest over three years and will be exercisable for ... of $1.40 per stock option. About Covalon ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Medical Affairs Capabilities Expanding in Emerging Marketplaces 2Covalon Announces Issuance of Stock Options 2
... Aug. 8, 2011 Systech International®, the recognized global ... leading systems engineering, automation, and manufacturing optimization services company, ... for the pharmaceutical market in Puerto Rico.  VCG now ... Systech and their extensive customer-base in region. ...
... 2011 - Pharmasset, Inc. (Nasdaq: VRUS ) announces ... to be held August 10 to 11, 2011 at the ... Executive Officer, will provide an overview of the company at ... 9:30 AM (ET). To access a simultaneous webcast ...
Cached Medicine Technology:Systech Selects Vantage Consulting Group as their Sales Agent in Puerto Rico 2Systech Selects Vantage Consulting Group as their Sales Agent in Puerto Rico 3Pharmasset to Present at Canaccord Genuity Growth Conference 2Pharmasset to Present at Canaccord Genuity Growth Conference 3
(Date:3/29/2015)... (PRWEB) March 30, 2015 Over 50 ... symptoms tied to undiagnosed autoimmune, thyroid, or hormone disorders. ... disorders, has personally treated hundreds of patients dealing with ... unaware of the treatment options for their ailments. Her ... solutions to women living with fatigue, brain fog, and ...
(Date:3/29/2015)... 29, 2015 Women’s Excellence , ... Secondary to their location in Birmingham, they now ... They continue to be affiliated with Crittenton, St. ... Menopause is a normal condition that all women experience ... of the changes a woman goes through either just ...
(Date:3/29/2015)... Nashville, TN (PRWEB) March 29, 2015 ... insurance that agencies promote nationally on the web can ... of permanent life insurance quotes can now be explored ... http://quotespros.com/life-insurance.html . , Learning the differences between what ... offers can be a challenge for some men and ...
(Date:3/29/2015)... March 29, 2015 The culmination of one ... coming when the Final Four invades Lucas Oil ... has been one filled with excitement, buzzer-beaters, and of course, ... busted, superstars have been made, and future professional products have ... down to the four teams that advanced through their regional ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... clinical trials and research, manage data results and ... their clients reach regulation standards. Contract research organizations ... medical device manufacturing sectors. Industry operators provide clients ... to late-stage clinical research for Food and Drug ...
Breaking Medicine News(10 mins):Health News:How to Turn Mid-life into the Good Life 2Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Menopause 2Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Cheap 2015 Final Four Tickets: Ticket Down Slashes Kentucky Wildcats and Wisconsin Badgers Final Four Tickets at Lucas Oil Stadium and Issues Valuable Promo Code 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4
... Healthy, middle-aged smokers who take the most popular smoking cessation ... of being hospitalized with a heart attack or other serious ... Hopkins-led study suggests. "People want to quit smoking to ... they,re taking a drug that increases the risk for the ...
... Phoenix, AZ, USA July 4, 2011 VisionGate, ... the early detection of lung cancer, today announced that ... its LuCED test can improve the utility of low ... detection of lung cancer in high risk individuals. ...
... News) -- Staying hydrated is critical if you,re physically active ... so you need to assess your personal sweat rate, according ... "Sweat rate is very simple to calculate: weigh yourself ... half an hour and don,t drink or use the bathroom ...
... FRIDAY, July 1 (HealthDay News) -- Preschool children need to ... the true concept of counting, according to researchers. "We ... to involve counting. It,s only when children go beyond three ... are," lead author Elizabeth Gunderson, a graduate student in psychology ...
... , FRIDAY, July 1 (HealthDay News) -- A new ... a certain type of learning remarkable staying power. Over ... face or pattern from a larger group of images. They ... practice. When they were tested again one to two years ...
... citywide study published online in today,s issue of ... disparities in the use of clot-busting drugs to treat acute ... According to the study,s results, significantly fewer black patients receive ... emergency care and the presence of medical conditions that exclude ...
Cached Medicine News:Health News:Smokers using varenicline to quit the habit at greater risk of heart attack 2Health News:IASLC: Adjunctive use of 3-D imaging system increases utility of CT lung cancer screening 2Health News:IASLC: Adjunctive use of 3-D imaging system increases utility of CT lung cancer screening 3Health News:How to Stay Hydrated in Hot Weather 2Health News:Understanding Numbers Isn't as Simple as 1, 2, 3 2Health News:When It Comes to Memory, Practice Seems to Make Perfect 2Health News:Citywide study shows racial disparities in emergency stroke treatment 2
... High performance plus simple ... gentle and efficient washing ... is performed with minimum ... cells while membrane bound ...
Stat Fax 2600 is fully automatic microplate washer....
The Microtech Microplate Washer (220 V) is a flexible and ultra compact microplate washer. The system offers a wide choice of washing functions and sequences designed to handle most any microplate ap...
... a powerful, compact and programmable 2 ... vacuum and dispensing pumps. Dispense and ... vertical and horizontal needle positioning in ... wash and waste bottles and vacuum ...
Medicine Products: